NCT02083484 2018-01-26Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)Merck Sharp & Dohme LLCNo longer available